Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Industry News
Share your love
Oculus Introduces Pentacam Cornea OCT at ESCRS 2024
Oculus has unveiled the Pentacam Cornea OCT, an innovative device that integrates Scheimpflug imaging with the world’s first pericentric OCT scanning system. This dual imaging technology captures both Scheimpflug and ultra high-resolution OCT images of the cornea in just one…
Dangers of Eye Color-Changing Drops: Ophthalmologists Warn
The American Academy of Ophthalmology is warning the public about over-the-counter eye drops that claim to change eye color. These products, popularized on social media platforms like TikTok, are unproven, unregulated, and could pose significant risks to eye health. Unapproved…
Opus Genetics Receives FDA RPD Designation for OPGx-LCA5
Research Triangle Park, N.C. – August 20, 2024 – Opus Genetics has announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for its ocular gene therapy, OPGx-LCA5, which aims to treat patients with…
Sandoz Receives FDA Approval for ENZEEVU™
Sandoz has secured FDA approval for ENZEEVU™ (aflibercept-abzv), a biosimilar to EYLEA®, to treat retinal conditions like wet age-related macular degeneration (AMD) and diabetic retinopathy. This approval strengthens Sandoz’s U.S. biosimilar portfolio, offering a cost-effective alternative for managing retinal diseases.…
AMD Explained: Tips for Safeguarding Your Vision
The eyes are often called the windows to the soul, but what happens when those windows become cloudy and blurred? That’s the reality for millions suffering from age-related macular degeneration (AMD), which can rob you of your precious eyesight as…
Exclusive: Key Events at ESCRS 2024
The 42nd of the European Society of Cataract and Refractive Surgeons (ESCRS) is poised to offer a dynamic array of events and initiatives in 2024, featuring a mix of educational programs, commemorative milestones, and new insights into key areas of…
FDA Notifies Ocugen to Begin Expanded Access Program RP
The FDA has authorized Ocugen, Inc. to launch an expanded access program (EAP) for patients aged 18 and older with retinitis pigmentosa (RP), providing early access to its promising gene therapy candidate, OCU400. The treatment has shown encouraging results in…
Bausch + Lomb’s TENEO Laser Achieves Strong LASIK Outcomes
Bausch + Lomb recently published the results of a pivotal clinical trial for its TENEO™ Excimer Laser in the Journal of Refractive Surgery. This study, which played a crucial role in securing U.S. FDA approval for the device in January…
Eyenovia and SGN Nanopharma to Develop Dry Eye Treatment
Eyenovia and SGN Nanopharma have announced a new collaboration to develop a treatment for chronic dry eye disease. Eyenovia, known for its two FDA-approved products and a late-stage asset in pediatric progressive myopia, will work with SGN Nanopharma to develop…
Novaliq’s Vevizye® Receives Positive CHMP Opinion for DED
Novaliq announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion recommending the granting of a marketing authorization for Vevizye® in the European Union. This therapy is designed to treat moderate…